A. V. Balashova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. V. Balashova has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Irina Vladimirovna Glinkina
Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Lubov V. Matchekhina
Russian Gerontology Research and Clinical Centre, Pirogov National Research Medical University, Moscow 129226, Russia
3 shared publications - Olga Nikolaevna Tkacheva
Russian Gerontology Clinical Research Center of Pirogov Russian National Research Medical University
3 shared publications - Valentin Viktorovich Fadeyev
Lomonosov Moscow State University
3 shared publications - A. S. Shyman
Sechenov University
2 shared publications - A. V. Oderiy
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications
Latest Publications
- Open Access
- 30 March 2024
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 1,p. 21-29
Vitamin D and Geriatric Assessment: A Cross-Sectional Study on the Cohort of Centenarians in the Central Region of Russian Federation
Background. The trend towards aging of the population is global, which makes the study of etiology, prevention and treatment of age-related disorders relevant. Increasing number of studies highlights the influence of 25-hydroxyvitamin D deficiency on health state in older people, as well as its correlation with geriatric syndromes prevalence. However, at the moment it is not known whether these patterns persist in patients older than 90 due to the limited number of studies on this population.Aim. To assess the prevalence of vitamin D deficiency in a cohort of centenarians in the central region of Russian Federation and to study its relationship with the presence of geriatric syndromes.Materials and methods. The study was carried out by Russian Gerontology Research and Clinical Centre of Pirogov Russian National Research Medical University and Center for Strategic Planning and Management of Medical and Biological Health Risks. It was a cross-sectional study on the cohort of centenarians (90 years and older). Complex geriatric assessment was performed. Complex geriatric assessment included past medical history, geriatric scales and questionnaires (MMSE, SARC-F, MNA scores). Blood samples were taken to assess the 25-OH vitamin D levels using chemiluminescence method. The study is reviewed by the ethics committee (№ 30 24.12.2019). The statistical analysis was performed using Python version 3.9 and R version 4.1.3.Results. The study included 3,235 people aged 90 to 107 years. Median level of 25-hydroxyvitamin D was 9 ng/ml, 86.7% of participants were found to be 25(OH)D deficient, and in 8.3% insufficiency 25(OH)D was detected. Using the intergroup analysis, the association between 25-OH vitamin D levels and some geriatric syndromes, such as malnutrition, sarcopenia and cognitive impairment was observed. However, after adjusting to physical activity and nutrition statistically significant association was demonstrated only for cognitive impairment.Conclusion. The results obtained on the association between low levels of 25-OH vitamin D and cognitive impairment among centenarians confirm the importance of vitamin D deficiency prevention and might be starting point for future studies.
- 30 March 2024
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 1,p. 21-29
Open AccessVitamin D and Geriatric Assessment: A Cross-Sectional Study on the Cohort of Centenarians in the Central Region of Russian Federation
Background. The trend towards aging of the population is global, which makes the study of etiology, prevention and treatment of age-related disorders relevant. Increasing number of studies highlights the influence of 25-hydroxyvitamin D deficiency on health state in older people, as well as its correlation with geriatric syndromes prevalence. However, at the moment it is not known whether these patterns persist in patients older than 90 due to the limited number of studies on this population.Aim. To assess the prevalence of vitamin D deficiency in a cohort of centenarians in the central region of Russian Federation and to study its relationship with the presence of geriatric syndromes.Materials and methods. The study was carried out by Russian Gerontology Research and Clinical Centre of Pirogov Russian National Research Medical University and Center for Strategic Planning and Management of Medical and Biological Health Risks. It was a cross-sectional study on the cohort of centenarians (90 years and older). Complex geriatric assessment was performed. Complex geriatric assessment included past medical history, geriatric scales and questionnaires (MMSE, SARC-F, MNA scores). Blood samples were taken to assess the 25-OH vitamin D levels using chemiluminescence method. The study is reviewed by the ethics committee (№ 30 24.12.2019). The statistical analysis was performed using Python version 3.9 and R version 4.1.3.Results. The study included 3,235 people aged 90 to 107 years. Median level of 25-hydroxyvitamin D was 9 ng/ml, 86.7% of participants were found to be 25(OH)D deficient, and in 8.3% insufficiency 25(OH)D was detected. Using the intergroup analysis, the association between 25-OH vitamin D levels and some geriatric syndromes, such as malnutrition, sarcopenia and cognitive impairment was observed. However, after adjusting to physical activity and nutrition statistically significant association was demonstrated only for cognitive impairment.Conclusion. The results obtained on the association between low levels of 25-OH vitamin D and cognitive impairment among centenarians confirm the importance of vitamin D deficiency prevention and might be starting point for future studies.
- Open Access
- 11 September 2023
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Problems of Geroscience
- No. 1,p. 7-14
Senolytic drugs: implications for clinical practice
The aging mechanisms study is one of the most important aims in the field of geroscience and clinical medicine. There has been a wide range of fundamental research data accumulated on this matter. The processes associated with regeneration capability decrease, age-related decline of cell proliferation and resilience are highlighted in vitro studies, as well as on animal models, but their translation into clinical practice has not been carried out yet. Our aim was to study the most important mechanisms of aging and the ways of influencing on them with geroprotective technologies, such as senolytic medications. The relevance of this topic is confirmed by increasing number of launched clinical trials, but their results are often ambiguous and require further analysis and elimination of the identified difficulties and shortcomings. We have searched and analysed the literature over the past 10 years using Pubmed and Scopus, in order to find information about the main mechanisms of aging, and possible use of geroprotective medicatios in clinical practice.
- 11 September 2023
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Problems of Geroscience
- No. 1,p. 7-14
Open AccessSenolytic drugs: implications for clinical practice
The aging mechanisms study is one of the most important aims in the field of geroscience and clinical medicine. There has been a wide range of fundamental research data accumulated on this matter. The processes associated with regeneration capability decrease, age-related decline of cell proliferation and resilience are highlighted in vitro studies, as well as on animal models, but their translation into clinical practice has not been carried out yet. Our aim was to study the most important mechanisms of aging and the ways of influencing on them with geroprotective technologies, such as senolytic medications. The relevance of this topic is confirmed by increasing number of launched clinical trials, but their results are often ambiguous and require further analysis and elimination of the identified difficulties and shortcomings. We have searched and analysed the literature over the past 10 years using Pubmed and Scopus, in order to find information about the main mechanisms of aging, and possible use of geroprotective medicatios in clinical practice.
- Open Access
- 27 February 2023
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 19 (4) , 431-441
Metabolic adverse effects of antipsychotics: the state of the problem and management options
Antipsychotic drugs are widely used for many psychiatric disorders, such as schizophrenia, bipolar affective disorder, delusions and hallucinations due to neurological disorders, depression with severe psychotic symptoms. Metabolic disorders including weight gain, dyslipidemia and hyperglycemia are one of the most common side effects of antipsychotic therapy. Psychiatric patients have higher risk of cardiovascular disease, so that the development of metabolic side effects is an important clinical problem that should be solved. Antipsychotic-induced weight gain may cause distress that leads to antipsychotics withdraw and repeated hospitalizations.Lifestyle changes, correction of the antipsychotic treatment, additional medications and their combination are the possible solutions of antipsychotic metabolic side effects. Lifestyle modification is a first-line therapy that should complement other options, when it feasible. At the same time, it can be extremely difficult for patients receiving antipsychotic to adhere dietary and physical activity recommendations. Replacing an antipsychotic with a milder drug is not always possible and may not be enough effective. Metformin seems to be the most well-studied, safe and effective agent that is prescribed to deal with antipsychotic-induced weight gain and associated metabolic disorders. Glucagon-like peptide type 1 receptor agonists and thiazolidinediones are mentioned as alternative medications, but clinical data on their efficacy and safety in this patient group are extremely limited. Dyslipidemia can develop as an independent antipsychotic side effect even without an increase in body weight. The most effective treatment, as in the general population, is statin therapy. However, the joint appointment of statins and antipsychotic significantly increases the risk of adverse reactions, such as myalgia, myopathy, increased creatine kinase levels, due to the competition of drugs for the cytochrome system.It is still unknown what scales should be used for cardiovascular risk stratification in patients taking antipsychotic and whether it is possible to use metformin to prevent antipsychotic-induced weight gain, and if so, how to select patients for whom such therapy can be indicated. Finally, more clinical trials are needed to evaluate the efficacy and safety of other classes of hypoglycemic and lipid-lowering drugs in patients on antipsychotics.
- 27 February 2023
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 19 (4) , 431-441
Open AccessMetabolic adverse effects of antipsychotics: the state of the problem and management options
Antipsychotic drugs are widely used for many psychiatric disorders, such as schizophrenia, bipolar affective disorder, delusions and hallucinations due to neurological disorders, depression with severe psychotic symptoms. Metabolic disorders including weight gain, dyslipidemia and hyperglycemia are one of the most common side effects of antipsychotic therapy. Psychiatric patients have higher risk of cardiovascular disease, so that the development of metabolic side effects is an important clinical problem that should be solved. Antipsychotic-induced weight gain may cause distress that leads to antipsychotics withdraw and repeated hospitalizations.Lifestyle changes, correction of the antipsychotic treatment, additional medications and their combination are the possible solutions of antipsychotic metabolic side effects. Lifestyle modification is a first-line therapy that should complement other options, when it feasible. At the same time, it can be extremely difficult for patients receiving antipsychotic to adhere dietary and physical activity recommendations. Replacing an antipsychotic with a milder drug is not always possible and may not be enough effective. Metformin seems to be the most well-studied, safe and effective agent that is prescribed to deal with antipsychotic-induced weight gain and associated metabolic disorders. Glucagon-like peptide type 1 receptor agonists and thiazolidinediones are mentioned as alternative medications, but clinical data on their efficacy and safety in this patient group are extremely limited. Dyslipidemia can develop as an independent antipsychotic side effect even without an increase in body weight. The most effective treatment, as in the general population, is statin therapy. However, the joint appointment of statins and antipsychotic significantly increases the risk of adverse reactions, such as myalgia, myopathy, increased creatine kinase levels, due to the competition of drugs for the cytochrome system.It is still unknown what scales should be used for cardiovascular risk stratification in patients taking antipsychotic and whether it is possible to use metformin to prevent antipsychotic-induced weight gain, and if so, how to select patients for whom such therapy can be indicated. Finally, more clinical trials are needed to evaluate the efficacy and safety of other classes of hypoglycemic and lipid-lowering drugs in patients on antipsychotics.
- Open Access
- 5 December 2022
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 176-185
Nursing protocol: diabetes complication prevention in older patients
Older inpatient with diabetes mellitus is highly vulnerable to acute diabetes complications. Awareness-raising program for nursing staff is aimed to shed the light on risk factors and thereby reduce diabetic complications frequency, and to implement clear algorithm of actions to cope complications when they occur minimize consequences for the patient and the clinic.
- 5 December 2022
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 176-185
Open AccessNursing protocol: diabetes complication prevention in older patients
Older inpatient with diabetes mellitus is highly vulnerable to acute diabetes complications. Awareness-raising program for nursing staff is aimed to shed the light on risk factors and thereby reduce diabetic complications frequency, and to implement clear algorithm of actions to cope complications when they occur minimize consequences for the patient and the clinic.
- Open Access
- 18 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 22-32
Special considerations in the therapeutic education of elderly with diabetes mellitus type 2
Diabetes self-management education (DSME) is an essential part of effective and safe treatment of chronic conditions such as diabetes mellitus (DM). Though the data on DSME effectiveness in elderly are limited, all patients should be educated regardless of age. The form of learning and education program may vary depending on the clinical situation and the patient’s characteristics. Age-related problems, so-called geriatric syndromes, determinant heterogeneity of elderly diabetic population. Geriatric syndromes should be taken into account to choose proper treatment goals and optimal education programs. Functional dependency, cognitive decline, depression, sarcopenia, malnutrition and polypharmacy seems to be most important in the education context. The development of geriatric education program with a broad focus on solving both diabetic and age-related problems and its implementation on a wider range of institutions may be useful to improve diabetes self-management education of elderly in clinical practice. It is also necessary to initiate clinical studies to evaluate DSME effectiveness in elderly not only from the generally accepted diabetological criteria, but also considering its impact on age-related problems.
- 18 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 22-32
Open AccessSpecial considerations in the therapeutic education of elderly with diabetes mellitus type 2
Diabetes self-management education (DSME) is an essential part of effective and safe treatment of chronic conditions such as diabetes mellitus (DM). Though the data on DSME effectiveness in elderly are limited, all patients should be educated regardless of age. The form of learning and education program may vary depending on the clinical situation and the patient’s characteristics. Age-related problems, so-called geriatric syndromes, determinant heterogeneity of elderly diabetic population. Geriatric syndromes should be taken into account to choose proper treatment goals and optimal education programs. Functional dependency, cognitive decline, depression, sarcopenia, malnutrition and polypharmacy seems to be most important in the education context. The development of geriatric education program with a broad focus on solving both diabetic and age-related problems and its implementation on a wider range of institutions may be useful to improve diabetes self-management education of elderly in clinical practice. It is also necessary to initiate clinical studies to evaluate DSME effectiveness in elderly not only from the generally accepted diabetological criteria, but also considering its impact on age-related problems.
- Open Access
- 1 August 2021
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 261
Ways of polypharmacy optimization in elderly patients with type 2 diabetes mellitus
Современные достижения фармакотерапии — залог компенсации и сдерживания прогрессирования многих заболеваний. Основной задачей современной медицины является увеличение продолжительности качественной жизни пациентов с хроническими заболеваниями.
- 1 August 2021
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 261
Open AccessWays of polypharmacy optimization in elderly patients with type 2 diabetes mellitus
Современные достижения фармакотерапии — залог компенсации и сдерживания прогрессирования многих заболеваний. Основной задачей современной медицины является увеличение продолжительности качественной жизни пациентов с хроническими заболеваниями.
- Open Access
- 1 August 2021
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 259
The Epidemiology of Cognitive impairment in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors
Цель: оценить распространенность когнитивных нарушений (КН) у пожилых пациентов с сахарным диабетом (СД) 2 типа.
- 1 August 2021
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 259
Open AccessThe Epidemiology of Cognitive impairment in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors
Цель: оценить распространенность когнитивных нарушений (КН) у пожилых пациентов с сахарным диабетом (СД) 2 типа.
- Open Access
- 12 May 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 56-67-67
Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
Elderly patients with diabetes type 2 represent complex and heterogeneous group with different diabetes complications and comorbidity, polypharmacy, functional and cognitive state. Each of those factors should be taken into account to choose the best glycemic targets as well as the most tailored treatment so that it is necessary for endocrinologist to perform geriatric assessment. The most favorable antidiabetic drugs for elderly are safe in terms of hypoglycemia and cardiovascular risks, can be used irrespective of kidney function, do not affect weight or bone mineral density, and are available in fixed combinations with other drugs. Dipeptidyl pepti-dase-4 (DPP-4) inhibitors meet all these requirements with low adverse events rate. Interdisciplinary approach, close interaction with patient and his relatives and considerations for both intensification and deprescribing are keys to successful treatment in this patient subgroup. Cardiovascular events are the most common cause of death and hypoglycemia is highly unfavorable in elderly because it can lead to falls, life-threatening arrhythmias, and cognitive impairment. So deprescribing in elderly with diabetes should be primarily aimed at minimizing of cardiovascular events and severe hypoglycemia risks. For this purpose, it is considered to the reject use of sulfonylureas, glinides, insulins in favor of safer ones (metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors).
- 12 May 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 56-67-67
Open AccessFactors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
Elderly patients with diabetes type 2 represent complex and heterogeneous group with different diabetes complications and comorbidity, polypharmacy, functional and cognitive state. Each of those factors should be taken into account to choose the best glycemic targets as well as the most tailored treatment so that it is necessary for endocrinologist to perform geriatric assessment. The most favorable antidiabetic drugs for elderly are safe in terms of hypoglycemia and cardiovascular risks, can be used irrespective of kidney function, do not affect weight or bone mineral density, and are available in fixed combinations with other drugs. Dipeptidyl pepti-dase-4 (DPP-4) inhibitors meet all these requirements with low adverse events rate. Interdisciplinary approach, close interaction with patient and his relatives and considerations for both intensification and deprescribing are keys to successful treatment in this patient subgroup. Cardiovascular events are the most common cause of death and hypoglycemia is highly unfavorable in elderly because it can lead to falls, life-threatening arrhythmias, and cognitive impairment. So deprescribing in elderly with diabetes should be primarily aimed at minimizing of cardiovascular events and severe hypoglycemia risks. For this purpose, it is considered to the reject use of sulfonylureas, glinides, insulins in favor of safer ones (metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors).
- Open Access
- 1 May 2021
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 12 (1) , 60-73
Interdisciplinary problem of post-transplant diabetes mellitus: literature review
The number of transplantation and transplant survival rates increase steadily. Patients after solid organ transplantation re-ceive lifelong immunosuppressive therapy which may have adverse effects on carbohydrate and lipid metabolism. The most diabetogenic drugs are calcineurin inhibitors and corticosteroids. Posttransplant diabetes mellitus (PTDM) is hyperglycemia that meets American Diabetes Association and World Health Organization diabetes criteria for nontransplant patients and that was newly diagnosed after transplantation. PTDM may worsen both short-term and long-term transplantation outcomes so that the problem of timely diagnosis, proper treatment and prevention is critical. In early post-transplant period, transient hyperglycemia is found in the vast majority of patients; therefore, PTDM screening is carried out at least one month after transplantation. The gold standard test for PTDM diagnosis is oral glucose tolerance test. In the same time diagnostic value of hemoglobin A1C is limited. Lifestyle therapy and antidiabetic drugs are considered as possible preventive measures. Stress induced hyperglycemia management in solid organ recipients is the same with other surgical patients. Which organ was transplanted, patient characteristics and possible drug interactions with immunosuppressive therapy should be taken into account while managing PTDM. Blood pressure and lipid profile should be under control for comprehensive cardiovascu-lar risk reduction. It remains unclear which PTDM treatment and prevention strategy is the best and for better understanding interdisciplinary approach is needed.
- 1 May 2021
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 12 (1) , 60-73
Open AccessInterdisciplinary problem of post-transplant diabetes mellitus: literature review
The number of transplantation and transplant survival rates increase steadily. Patients after solid organ transplantation re-ceive lifelong immunosuppressive therapy which may have adverse effects on carbohydrate and lipid metabolism. The most diabetogenic drugs are calcineurin inhibitors and corticosteroids. Posttransplant diabetes mellitus (PTDM) is hyperglycemia that meets American Diabetes Association and World Health Organization diabetes criteria for nontransplant patients and that was newly diagnosed after transplantation. PTDM may worsen both short-term and long-term transplantation outcomes so that the problem of timely diagnosis, proper treatment and prevention is critical. In early post-transplant period, transient hyperglycemia is found in the vast majority of patients; therefore, PTDM screening is carried out at least one month after transplantation. The gold standard test for PTDM diagnosis is oral glucose tolerance test. In the same time diagnostic value of hemoglobin A1C is limited. Lifestyle therapy and antidiabetic drugs are considered as possible preventive measures. Stress induced hyperglycemia management in solid organ recipients is the same with other surgical patients. Which organ was transplanted, patient characteristics and possible drug interactions with immunosuppressive therapy should be taken into account while managing PTDM. Blood pressure and lipid profile should be under control for comprehensive cardiovascu-lar risk reduction. It remains unclear which PTDM treatment and prevention strategy is the best and for better understanding interdisciplinary approach is needed.